Details

Autor(en) / Beteiligte

• Guo, Huifang
• German, Peter
• Bai, Shanshan
• Barnes, Sean
• Guo, Wei
• Qi, Xiangjie
• Lou, Hongxiang
• Liang, Jiyong
• Jonasch, Eric
• Mills, Gordon B.
• Ding, Zhiyong

Titel

The PI3K/AKT Pathway and Renal Cell Carcinoma

Ist Teil von

• Journal of genetics and genomics, 2015-07, Vol.42 (7), p.343-353

Ort / Verlag

China: Elsevier Ltd

Erscheinungsjahr

2015

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• The phosphatidylinositol 3 kinase （PI3K）/AKT pathway is genetically targeted in more pathway components and in more tumor types than any other growth factor signaling pathway, and thus is frequently activated as a cancer driver. More importantly, the PI3K/AKT pathway is composed of multiple bifurcating and converging kinase cascades, providing many potential targets for cancer therapy. Renal cell carcinoma （RCC） is a high-risk and high-mortality cancer that is notoriously resistant to traditional chemotherapies or radiotherapies. The PI3K/AKT pathway is modestly mutated but highly activated in RCC, representing a promising drug target. Indeed, PI3K pathway inhibitors of the rapalog family are approved for use in RCC. Recent large-scale integrated analyses of a large number of patients have provided a molecular basis for RCC, reiterating the critical role of the PI3K/AKT pathway in this cancer. In this review, we summarize the genetic alterations of the PI3K/AKT pathway in RCC as indicated in the latest large-scale genome sequencing data, as well as treatments for RCC that target the aberrant activated PI3K/AKT pathway.